001), with risk increased by 28% and 71% in the youngest and oldest patients. The effect of age was most marked during the first year of follow-up ( P <. The relationship with age remained significant after adjustment for sex and performance status ( P <. 001), with declining risk between these extremes. In the analysis of overall survival, compared with patients aged approximately 57 years, who constituted the reference group with lowest risk, the youngest patients (ie, those near age 18 years) had a 19% increased risk of death and the oldest patients (ie, those near age 90 years) had a 42% increased risk ( P <. Increased Risk in Younger and Older Patients Overall, median progression-free survival was 8.1 months and median overall survival was 17.9 months. Median follow-up among surviving patients was 18 months.

Mean age differed significantly by sex and performance status. Patients had a mean age of 62 years, with 4% aged в‰¤ 40 years and 14% aged < 50 years 62% of patients were male, and performance status was 0 in 53% and 1 in 43%. The study included 20,023 patients from 24 first-line randomized trials in metastatic colorectal cancer with years of accrual from 1997 through 2010. The findings, reported in the Journal of Clinical Oncology, indicate a U-shaped risk of death and death or progression characterized by greatest risk among the youngest and oldest patients. Lieu et al recently analyzed the effect of age on outcome in patients with metastatic colorectal cancer using the ARCAD (Aide et Recherche en CancГ©rologie Digestive) database. Risk of death or progression was greatest among the youngest and oldest patients, with increases in risk being greatest in the first-year of follow-up.Risk of death was greatest among the youngest and oldest patients, with increases in risk being greatest in the first-year of follow-up.

Free age progression